These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 15471994)

  • 1. Post-antifungal effect of amphotericin B and voriconazole against Aspergillus fumigatus analysed by an automated method based on fungal CO2 production: dependence on exposure time and drug concentration.
    Chryssanthou E; Sjölin J
    J Antimicrob Chemother; 2004 Nov; 54(5):940-3. PubMed ID: 15471994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-antifungal effect of amphotericin B and voriconazole against germinated Aspergillus fumigatus conidia.
    Chryssanthou E; Loebig A; Sjölin J
    J Antimicrob Chemother; 2008 Jun; 61(6):1309-11. PubMed ID: 18367461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparative study of the post-antifungal effect (PAFE) of amphotericin B, triazoles and echinocandins on Aspergillus fumigatus and Candida albicans.
    Manavathu EK; Ramesh MS; Baskaran I; Ganesan LT; Chandrasekar PH
    J Antimicrob Chemother; 2004 Feb; 53(2):386-9. PubMed ID: 14729762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparative study of fungicidal activities of voriconazole and amphotericin B against hyphae of Aspergillus fumigatus.
    Krishnan S; Manavathu EK; Chandrasekar PH
    J Antimicrob Chemother; 2005 Jun; 55(6):914-20. PubMed ID: 15824093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the post-antifungal effect (PAFE) of amphotericin B and nystatin against 30 zygomycetes using two different media.
    Vitale RG; Meis JF; Mouton JW; Verweij PE
    J Antimicrob Chemother; 2003 Jul; 52(1):65-70. PubMed ID: 12775672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study.
    Mallié M; Bastide JM; Blancard A; Bonnin A; Bretagne S; Cambon M; Chandenier J; Chauveau V; Couprie B; Datry A; Feuilhade M; Grillot R; Guiguen C; Lavarde V; Letscher V; Linas MD; Michel A; Morin O; Paugam A; Piens MA; Raberin H; Tissot E; Toubas D; Wade A
    Int J Antimicrob Agents; 2005 Apr; 25(4):321-8. PubMed ID: 15784312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between the E test and the CLSI M-38 A microdilution method to determine the activity of amphotericin B, voriconazole, and itraconazole against clinical isolates of Aspergillus fumigatus.
    Guinea J; Peláez T; Alcalá L; Bouza E
    Diagn Microbiol Infect Dis; 2007 Mar; 57(3):273-6. PubMed ID: 17141455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Sensititre YeastOne with the NCCLS M38-A microdilution method to determine the activity of amphotericin B, voriconazole, and itraconazole against clinical isolates of Aspergillus fumigatus.
    Guinea J; Peláez T; Alcalá L; Bouza E
    Diagn Microbiol Infect Dis; 2006 Sep; 56(1):53-5. PubMed ID: 16650953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of the inhibitory effect of voriconazole on the fungicidal activity of amphotericin B against Candida albicans in an in vitro kinetic model.
    Lignell A; Löwdin E; Cars O; Sjölin J
    J Antimicrob Chemother; 2008 Jul; 62(1):142-8. PubMed ID: 18408237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro susceptibilities of Aspergillus spp. causing otomycosis to amphotericin B, voriconazole and itraconazole.
    Kaya AD; Kiraz N
    Mycoses; 2007 Nov; 50(6):447-50. PubMed ID: 17944704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of antifungal drug susceptibilities of Aspergillus species by a fluorescence-based microplate assay.
    Balajee SA; Imhof A; Gribskov JL; Marr KA
    J Antimicrob Chemother; 2005 Jan; 55(1):102-5. PubMed ID: 15546970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new in-vitro kinetic model to study the pharmacodynamics of antifungal agents: inhibition of the fungicidal activity of amphotericin B against Candida albicans by voriconazole.
    Lignell A; Johansson A; Löwdin E; Cars O; Sjölin J
    Clin Microbiol Infect; 2007 Jun; 13(6):613-9. PubMed ID: 17378925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The evaluation of in vitro pharmacodynamic properties of amphotericin B, voriconazole and caspofungin against A. fumigatus isolates by the conventional and colorimetric time-kill assays.
    Kiraz N; Oz Y; Dag I
    Med Mycol; 2011 Aug; 49(6):594-601. PubMed ID: 21299374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential fungicidal activities of amphotericin B and voriconazole against Aspergillus species determined by microbroth methodology.
    Meletiadis J; Antachopoulos C; Stergiopoulou T; Pournaras S; Roilides E; Walsh TJ
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3329-37. PubMed ID: 17576838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase-dependent antifungal activity against Aspergillus fumigatus developing multicellular filamentous biofilms.
    Mowat E; Lang S; Williams C; McCulloch E; Jones B; Ramage G
    J Antimicrob Chemother; 2008 Dec; 62(6):1281-4. PubMed ID: 18819968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison between Aspergillus fumigatus conidia and hyphae susceptibilities to amphotericin B, itraconazole, and voriconazole by use of the mold rapid susceptibility assay.
    Wetter TJ; Hazen KC; Cutler JE
    Med Mycol; 2005 Sep; 43(6):525-32. PubMed ID: 16323310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activities of voriconazole, itraconazole and amphotericin B in vitro against 590 moulds from 323 patients in the voriconazole Phase III clinical studies.
    Espinel-Ingroff A; Johnson E; Hockey H; Troke P
    J Antimicrob Chemother; 2008 Mar; 61(3):616-20. PubMed ID: 18222957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the in-vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus.
    Cuenca-Estrella M; Rodríguez-Tudela JL; Mellado E; Martínez-Suárez JV; Monzón A
    J Antimicrob Chemother; 1998 Oct; 42(4):531-3. PubMed ID: 9818755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased frequency of non-fumigatus Aspergillus species in amphotericin B- or triazole-pre-exposed cancer patients with positive cultures for aspergilli.
    Lionakis MS; Lewis RE; Torres HA; Albert ND; Raad II; Kontoyiannis DP
    Diagn Microbiol Infect Dis; 2005 May; 52(1):15-20. PubMed ID: 15878437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid method for testing the susceptibility of Aspergillus fumigatus to amphotericin B, itraconazole, voriconazole and posaconazole by assessment of oxygen consumption.
    Araujo R; Coutinho I; Espinel-Ingroff A
    J Antimicrob Chemother; 2008 Dec; 62(6):1277-80. PubMed ID: 18824456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.